Mechanisms of selective motor neuron death in transgenic mouse models of motor neuron disease
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
To examine the mechanism(s) of disease underlying ALS, transgenic mouse models have been constructed that express aberrant neurofilaments or mutations in the abundant, cytoplasmic enzyme superoxide dismutase 1 (SOD1).In addition to progressive weakness arising from selective motor neuron death, mice expressing a modest level of a point mutant in neurofilament subunit NF-L show most of the pathologic hallmarks observed in familial and sporadic ALS, including perikaryal proximal axonal swellings, axonal degeneration, and severe skeletal muscle atrophy. Additional mice expressing familial ALS-linked mutations in the cytoplasmic enzyme SOD1, the only proven cause of ALS and which accounts for approximate 20% of familial disease, have demonstrated that at least one mutation causes disease through acquisition of an adverse property by the mutant enzyme, rather than elevation or loss of SOD1 activity. These animals not only provide a detailed look at the pathogenic progression of disease, but also represent a tool for testing hypotheses concerning the specific mechanism(s) of neuronal death and for testing therapeutic strategies.
NEUROLOGY 1996;47(Suppl 2): S54-S62
- Copyright 1996 by Advanstar Communications Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- Neurofilament misaccumulation as a cause of motor neuron disease.
- Neurofilament mutation as a cause of selective motor neuron death.
- SOD1 mutations in ALS: a toxic property, not increased or decreased SOD1 activity, causes disease in mice.
- Inferring mechanism of disease from the pathologic progression in FALS-linked SOD1 mutant mice.
- Proposed toxic property (or properties) of mutant SOD1.
- Conclusion.
- Discussion
- REFERENCES
- Figures & Data
- Info & Disclosures
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Article
Neurofilament light chainA prognostic biomarker in amyotrophic lateral sclerosisChing-Hua Lu, Corrie Macdonald-Wallis, Elizabeth Gray et al.Neurology, May 01, 2015 -
Article
Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosisEmily Feneberg, Patrick Oeckl, Petra Steinacker et al.Neurology, December 06, 2017 -
Article
Serum NFL discriminates Parkinson disease from atypical parkinsonismsTainá M. Marques, Anouke van Rumund, Patrick Oeckl et al.Neurology, February 27, 2019 -
Article
Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MSSinah Engel, Michaela Friedrich, Muthuraman Muthuraman et al.Neurology: Neuroimmunology & Neuroinflammation, July 19, 2019